Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Haploidentical vs matched donor transplantation in patients with myelofibrosis

Tania Jain • 12 Feb 2021
TCT 2021
Myelofibrosis Myeloproliferative Neoplasms

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, provides an overview of the outcomes of haploidentical donor transplantation versus matched donor allogeneic hematopoietic cell transplantations in patients with myelofibrosis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Tania Jain

3:31
PTCy based GvHD prophylaxis in myelofibrosis
Tania Jain • 12 Feb 2021
4:46
SIERRA trial updates: apamistamab in AML
Tania Jain • 12 Feb 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals